StockCall Research on Boston Scientific and Medtronic: Focus on Paroxysmal Atrial Fibrillation

LONDON, January 22, 2013 /PRNewswire/ –

The medical appliances and equipment industry faced its fair share of challenges
during the recession, as procedural volume in some cases was reduced due to the economic
situation in the U.S. and Europe. Analysts from our services research team completed
in-depth analysis on Boston Scientific Corporation (NYSE:BSX) and Medtronic Inc.
(NYSE:MDT). These free reports are available at

http://www.stockcall.com/registration

Competition also crimped margins for several companies, leading to lower sales and
profits. However, with the recession in the rear view mirror, the outlook for the industry
and companies such as Boston Scientific and Medtronic is positive. Now that companies have
been afforded some breathing room, they are focusing their attentions on bringing new
products to market and growing their international footprint. Download the free report on
Scientific by signing up now at

http://www.StockCall.com/BSX012213.pdf

Both Boston Scientific and Medtronic [Free Report on MDT
[http://www.stockcall.com/MDT012213.pdf ]][1] have been looking to new products to grow
their top- and bottom-lines, and both have recently been involved with paroxysmal atrial
fibrillation. Atrial fibrillation affects around 15 million people globally, and can cause
serious health problems such as strokes and heart failure.

In the case of Boston Scientific, the company newly announced that the first patient
has been treated in its ZERO AF clinical trial. The results of the trial are anticipated
to be used to back up an FDA regulatory submission for a paroxysmal atrial fibrillation
indication.

Medtronic has also been busy, recently stating that the FDA has cleared the FlexCath
Advance (TM) Steerable Sheath, an improvement to the Arctic Front Advance (TM) Cryoballon
System. The new sheath will make it easier to reach inferior veins of the heart when
delivering and positioning the cryoballoon catheter in the left atrium to treat paroxysmal
atrial fibrillation.

Footer:

        1) Medtronic Inc. Technical Analysis [
          http://www.StockCall.com/MedtronicInc012213.pdf ]

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and
comprehensive research and opinions on stocks making the headlines. Sign up today to talk
to our financial analyst at

http://www.stockcall.com

SOURCE StockCall.com